Vectura Opts For Tobacco Giant Philip Morris In Carlyle Takeover Tussle
‘Superior Cash Offer’ Worth £1.1bn Proves Decisive
Executive Summary
Vectura’s board of directors has chosen tobacco giant Philip Morris’s superior cash offer, turning down US private equity Carlyle, following a months-long battle between the two bidders for the inhalation specialist that was set to go to a rare auction in the UK.
You may also be interested in...
Deal Watch: Visus Begins Charting Its Direction In Ophthalmology With Two Deals
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
Philip Morris And Carlyle Go To Auction For Vectura
The Takeover Panel is stepping in to oversee an auction process after two revised offers in recent days from rivals Philip Morris and Carlyle upped the ante in the bidding war for the UK respiratory company.
One Foot In The Door? Trio Look To Reenter Annulled EU Generic Tecfidera Market
A topsy-turvy legal battle going back some years led to a raft of Tecfidera generics being pulled from the market in December last year. Now, three of the affected companies are a step closer to reentering the market, which is set to remain a Tecfidera monopoly until February 2025.